Comparative efficacy of Palbociclib and Everolimus with aromatase inhibitors in second line treatment of HR and HER2 negative metastatic breast cancer
Abstract Background Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) often develops resistance to endocrine therapy (ET), necessitating targeted therapies like Palbociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor). Thi...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer
2025-12-01
|
| シリーズ: | Discover Oncology |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1007/s12672-025-04330-0 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|